Ionis Pharmaceuticals, Inc. (IONS)
| Previous Close | 35.10 |
| Open | 32.89 |
| Bid | 29.53 x 1100 |
| Ask | 29.66 x 800 |
| Day's Range | 29.14 - 33.12 |
| 52 Week Range | 29.14 - 64.37 |
| Volume | 1,572,037 |
| Avg. Volume | 838,675 |
| Market Cap | 4.123B |
| Beta (5Y Monthly) | 1.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.97 |
| Earnings Date | Nov. 02, 2021 - Nov. 08, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 55.69 |
- Motley Fool
3 Stocks to Consider if the October Stock Market Sell-Off Worsens
In this Motley Fool Live video recorded on Oct. 6, Motley Fool contributors Keith Speights and Brian Orelli discuss three stocks to consider buying if the stock market sell-off worsens. Keith Speights: We're talking and we're nearly a full week into October right now, the stock market is off to a rocky start so far this month, quite a few biotech stocks and other healthcare stocks as well are down quite a bit already.
- GlobeNewswire
Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting
CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced topline results from its pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense oligonucleotide (ASO) drug being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), will be presented at the upcoming American Neurological Association (ANA) 2021 virtual meeting, October 17-19, 2021. ANA Presentation Details:Sunday, October 17, 2021, 4:20 p
- Motley Fool
3 Biotech Stocks With Huge Catalysts This Fall
Clinical trial results expected this fall could send shares of these stocks screaming higher, or lower.
